| abstract |
The present invention is directed to a nucleic acid molecule comprising a modified nucleotide, such as TGFs, including LNA, ENA, polyalkylene oxide, 2'-fluoro, 2'-O-methoxy and / or 2'- -Beta1, TGF-beta2, or 10-20 nucleotides of a selected region of a TGF-beta3 nucleic acid sequence. The present invention also relates to a pharmaceutical composition comprising such an oligonucleotide, wherein said composition or said oligonucleotide is selected from the group consisting of glaucoma, posterior capsitis, dry eye syndrome, Marfan or Roy-Diets syndrome, riboblastoma, , Macular degeneration, such as age-related macular degeneration, diabetic retinopathy, or cataracts. |